Articles By Anuja Singh
How AccurKardia’s Award-Winning AccurECG™ Platform Redefine ECG Diagnostics with AI?
Key Highlights: A Landmark Recognition for a Game-Changing ECG Technology AccurKardia’s AccurECG™ has been named the “Best New…
By
Can MIT and Recursion’s New AI Model Boltz-2 Slash Drug Discovery Time by 1000x…
Key Takeaways• Boltz-2 delivers AI-driven binding affinity predictions 1000x faster than traditional free energy methods—dramatically accelerating virtual screening…
Is Optic and Mechanica’s AI Venture Model the Future of Biotech Creation? Strategic Expansion…
Key Highlights Strategic Collaboration to Power AI-Led Biotech GrowthOptic, Inc., a pioneer in AI platforms for biopharma, has…
Is the OBI Pharma–TegMine Therapeutics ADC Deal the Next Leap in Precision Oncology Using…
Key Highlights 1. Powering the Next-Gen ADC Revolution: OBI’s GlycOBI® Meets TegMine’s TegMiner™The collaboration between Taiwan-based OBI Pharma…
Can AI Reveal the Hidden Biology of Cancer? Aitia and Gustave Roussy Join Forces…
Key Highlights: AI Collaboration to Decode Cancer ComplexityIn a bold step to redefine cancer treatment, Aitia, a leader…
Is Juvenescence’s Acquisition of Ro5 the Key to Unlocking AI-Driven Longevity Therapies in 2025?
Key Insights Juvenescence Acquires Ro5 to Bolster AI Capabilities in Drug DiscoveryJuvenescence Limited, a clinical-stage AI-enabled biotech company,…
How AccurKardia’s Award-Winning AccurECG™ Platform Redefine ECG Diagnostics with AI?
Key Highlights: A Landmark Recognition for a Game-Changing ECG Technology AccurKardia’s AccurECG™ has been named the “Best New…
Can MIT and Recursion’s New AI Model Boltz-2 Slash Drug Discovery Time by 1000x…
Key Takeaways• Boltz-2 delivers AI-driven binding affinity predictions 1000x faster than traditional free energy methods—dramatically accelerating virtual screening…
Is Optic and Mechanica’s AI Venture Model the Future of Biotech Creation? Strategic Expansion…
Key Highlights Strategic Collaboration to Power AI-Led Biotech GrowthOptic, Inc., a pioneer in AI platforms for biopharma, has…
Is the OBI Pharma–TegMine Therapeutics ADC Deal the Next Leap in Precision Oncology Using…
Key Highlights 1. Powering the Next-Gen ADC Revolution: OBI’s GlycOBI® Meets TegMine’s TegMiner™The collaboration between Taiwan-based OBI Pharma…
Can AI Reveal the Hidden Biology of Cancer? Aitia and Gustave Roussy Join Forces…
Key Highlights: AI Collaboration to Decode Cancer ComplexityIn a bold step to redefine cancer treatment, Aitia, a leader…
Is Juvenescence’s Acquisition of Ro5 the Key to Unlocking AI-Driven Longevity Therapies in 2025?
Key Insights Juvenescence Acquires Ro5 to Bolster AI Capabilities in Drug DiscoveryJuvenescence Limited, a clinical-stage AI-enabled biotech company,…